



Docket No.: 04654/1200494-US1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Balasubramanian Gopalan et al.

Application No.: 10/821,642

Confirmation No.: 9007

Filed: April 9, 2004

Art Unit: 1626

For: NOVEL HETEROCYCLIC COMPOUNDS
USEFUL FOR THE TREATMENT OF
INFLAMMATORY AND ALLERGIC
DISORDERS: PROCESS FOR THEIR
PREPARATION AND PHARMACEUTICAL
COMPOSITIONS CONTAINING THEM

Examiner: Y. L. Chu

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, attached hereto is a copy of Form PTO/SB/08 and copies of the documents listed thereon (except for copies of the issued U.S. patents).

U.S. Patent No. 3,846,553 is the U.S. counterpart to German Patent Publication No. 2059358, which was cited in the August 20, 2004 Information Disclosure Statement.

U.S. Serial No. 10/532,273 (citation AB) is a co-pending application which has three common inventors with the present application. U.S. Serial No. 10/532,273 is a national phase of and, therefore, has the same specification as International Publication No. WO 2004/037805 (citation BD). A copy of International Publication No. WO 2004/037805 is submitted herewith.

Therefore, applicants respectfully submit that the requirement under 37 CFR 1.98(a)(2)(iii) for a copy of the specification, claims, and drawings of U.S. Serial No. 10/532,273 has been satisfied.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO/SB/08) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing Form PTO/SB/08 next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.


It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Submitted herewith is the fee of \$180 required with this IDS. The Commissioner is authorized to charge any deficiency of up to \$2,000.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: April 28, 2006

Respectfully submitted,

By



Jay P. Lessler

Registration No.: 41,151

(212) 527-7700

(212) 527-7701 (Fax)

Attorneys/Agents For Applicant



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/821,642-Conf. #9007
				Filing Date	April 9, 2004
				First Named Inventor	Balasubramanian Gopalan
				Art Unit	1626
				Examiner Name	Y. L. Chu
Sheet	1	of	1	Attorney Docket Number	04654/1200494-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	3,846,553	11-05-1974	Shen et al.	
	AB	10/532,273		Balasubramanian et al.	
	AC	6,110,962	08/29/2000	Wrobel et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO 99/58521	11-18-1999	American Home Products Corp.		
	BB	WO 96/03377	02-08-1996	Sankyo Company, Limited		
	BC	JP 63 014156	06-21-1988	Canon Inc.		
	BD	WO 2004/037805	05-06-2004	Glenmark Pharmaceuticals Ltd.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	NIELSEN, K.F. et al, Fungal metabolite screening: database of 474 mycotoxins and fungal metabolites for dereplication by standardised liquid chromatography-UV-mass spectrometry methodology. <i>Journal of Chromatography</i> 1002, 1-2:111-136	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--